ImmunityBio, Inc. (IBRX)

The human immune system exists to recognize and destroy cells that do not belong — viruses, bacteria, and cells that have gone cancerous. Yet cancer cells are skilled at hiding: they evolve to look like normal cells, to suppress the immune signals that would trigger their own destruction, and to create a physical environment around themselves that dampens immune attack. For decades, cancer treatment has relied on blunt instruments: surgery to remove the tumor, chemotherapy and radiation that kill cancer cells but damage healthy cells along the way, and hormonal therapies that interrupt the signals cancer cells depend on. These approaches work for many patients, but many cancers either resist them or develop resistance over time, and the side effects can be severe.

A different approach has been gaining ground over the past fifteen years: harnessing the immune system itself to recognize and kill cancer. Rather than poisoning the cancer cells directly, immunotherapy works by removing the brakes cancer cells put on the immune system, or by teaching immune cells to recognize cancer as an enemy worth attacking. ImmunityBio was founded to pursue one specific approach: using natural killer cells — a type of immune cell that evolved to kill virus-infected and abnormal cells — to attack cancer.

Natural killer cells are conceptually appealing for cancer therapy because unlike other immune cells, they do not require the complex signaling and priming that most immune cells need to become activated. A natural killer cell recognizes certain warning signals on an abnormal cell and can kill it directly. But natural killer cells are rare in the blood, they exhaust quickly, and they do not survive well outside the body. The challenge that ImmunityBio set out to solve is how to take natural killer cells, expand them in the laboratory to large numbers, activate them against cancer, and reinfuse them into patients where they will survive, circulate, and kill cancer cells.

ImmunityBio’s approach has evolved as the company has developed. The early strategy relied on engineering natural killer cells to express a CAR — a chimeric antigen receptor — that gives them the ability to recognize and kill cancer cells expressing a specific antigen. This CAR-NK approach borrows the concept from CAR-T cell therapies, which have been transformative for treating certain blood cancers, but applies it to natural killer cells instead. The advantage of natural killer cells is that they are less likely to cause the severe inflammatory side effects that CAR-T therapies sometimes trigger. The disadvantage is that they are harder to expand and less durable — they do not persist as long as CAR-T cells do.

Beyond CAR-NK therapy, ImmunityBio has assembled a pipeline of related immunotherapies. The company is developing off-the-shelf therapies using allogeneic — donor-derived — natural killer cells that can be given to many patients rather than requiring personalized engineering for each patient. It is also developing therapeutic vaccines designed to teach the immune system to recognize cancer, and combination therapies that pair natural killer cell therapy with checkpoint inhibitors, drugs that remove the brakes cancer cells use to suppress immune attack.

The company’s development has been challenging. Clinical trials in oncology are lengthy and expensive, and failure rates are high; most drugs that enter clinical testing never reach the market. ImmunityBio has had clinical setbacks — trials that did not meet their primary endpoints, drugs that showed unexpected toxicity, and competitive developments that shifted the landscape. The field of cell therapy and immunotherapy is crowded, with many companies pursuing similar strategies, and proof of efficacy in the clinic is what separates success from failure.

ImmunityBio’s most advanced programs are in early to mid-stage clinical trials. The company is testing its therapies in multiple cancer types, including hematologic malignancies like leukemia and lymphoma where other immunotherapies have shown efficacy, and in solid tumors like ovarian cancer and colorectal cancer where immunotherapy has been harder to make work. The results from these trials will ultimately determine whether ImmunityBio’s approach has practical value. A therapy that works brilliantly in the laboratory but does not benefit patients in the clinic is worthless, and conversely, even a therapy with modest efficacy can create enormous value if it addresses a large, underserved population.

The fundamental business model in biotechnology at ImmunityBio’s stage is speculative. The company does not yet have approved products generating revenue. It burns cash funding research and development and clinical trials, generating no offsetting income. The company has raised capital from investors betting that the technology will eventually prove itself and that they will be rewarded with stock gains if ImmunityBio develops a successful drug. The company’s value, therefore, rests almost entirely on the probability that one or more of its development programs will succeed, and on the potential market size if they do.

Biotechnology companies at this stage are often valued by the market based on the perceived promise of their pipeline, the quality of their science and their team, and the competitive position they occupy. ImmunityBio competes for investor capital and attention against dozens of other cell-therapy and immunotherapy companies at similar or earlier stages of development. Some of those competitors have backing from larger pharmaceutical companies, which provides capital and expertise but also constrains independence. Others are pure plays, dependent on reaching milestones and raising capital on the venture market repeatedly to survive.

The risks are correspondingly high. Any single clinical trial could show that a therapy does not work or is unsafe, triggering a setback. Larger competitors could develop superior approaches and dominate the market if therapies eventually succeed. Regulatory agencies could impose requirements that make development more expensive or slow down timelines. And even if a therapy is successful, bringing it to market requires manufacturing at scale, navigating reimbursement decisions by insurance companies and healthcare systems, and building a commercial organization to sell it. Many biotechnology companies with promising science have failed at commercialization despite having a viable product.

What gives ImmunityBio its reason for existing is the unmet need it is trying to address. Cancer remains a leading cause of death worldwide, and many cancers have limited treatment options. If natural killer cell therapies can expand the toolkit of immunotherapies available to physicians, even for a subset of patients and cancers, the value could be substantial. The question is whether the company’s specific approach — using natural killer cells rather than other immune cells, and using allogeneic cells rather than personalized engineering — will prove superior to the many alternative approaches being pursued. That question will be answered in the clinic over the next five to ten years.

For investors, understanding ImmunityBio requires understanding both the science and the clinical landscape. The 10-K filing (SEC CIK 0001326110) describes the company’s program portfolio and the status of each. Clinical trial results, when published in scientific journals or presented at conferences, provide the most direct evidence of whether the approach is working. Comparing ImmunityBio’s results to those of competitors pursuing similar strategies shows whether the company is ahead, behind, or on par. And tracking the company’s cash runway — how long the existing capital can sustain operations before additional fundraising is needed — is essential to understanding the timeline to either a major clinical success or financial pressure that could force strategic partnerships or acquisitions.